Prostate Cancer Drug Enzalutamide Extends Lives but Fails the Cost-Effectiveness Test at Current Prices
A within-trial economic analysis of the ENZAMET phase 3 trial finds that enzalutamide significantly extends survival in metastatic hormone-sensitive prostate ...
